Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Biogen Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2009 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

NCT02052791
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

NCT05119790
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C] BIIB122 ([14C] DNL151)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

NCT00468546
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MabThera/Rituxan, Methotrexate, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 17, 2026, 7:16 AM EDT
Terminated Phase 4 Interventional Results available

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

NCT02241785
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Fullerton, California • Aurora, Colorado • Des Moines, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

NCT02341482
View directory record Official record
Conditions
Healthy
Interventions
PF-04958242, Itraconazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

NCT01610310
View directory record Official record
Conditions
Healthy, Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS), BIIB017 (peginterferon beta-1a) Autoinjector
Device
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

NCT01873417
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
BG00012 (DMF)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
37
States / cities
Cullman, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 2 Interventional Results available

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

NCT02142959
View directory record Official record
Conditions
Breast Cancer
Interventions
Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion, 3D conformal radiation therapy
Drug · Radiation
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

NCT00186589
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT)
Interventions
90Y Ibritumomab tiuxetan
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 17, 2026, 7:16 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation

NCT02217982
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Simethicone, Loperamide, Peanut Butter
Drug · Other
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 2Phase 3 Interventional

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

NCT00223301
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (cellcept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 2 Interventional Results available

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT00280241
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

NCT00675701
View directory record Official record
Conditions
Healthy
Interventions
placebo, lixivaptan, moxifloxacin
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 17, 2026, 7:16 AM EDT
Terminated Phase 3 Interventional Results available

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

NCT03068130
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 4 Interventional

Community Based Trial for AMEVIVE®

NCT00168753
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Fairhope, Alabama • Anchorage, Alaska + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 17, 2026, 7:16 AM EDT
Not listed Phase 4 Interventional

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

NCT04048577
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dosing Interruption of Natalizumab
Drug
Lead sponsor
Berkovich, Regina MD, PhD Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RTA 408 Lotion in Healthy Volunteers

NCT02029716
View directory record Official record
Conditions
Healthy
Interventions
RTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional

RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies

NCT00529438
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoid Malignancies
Interventions
Bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

NCT00048555
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
IDEC-114
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

NCT00674063
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
11
States / cities
Hot Springs, Arkansas • Fridley, Minnesota • Omaha, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 17, 2026, 7:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

NCT04494256
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB105, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 17, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

NCT03764488
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tofersen, 99mTc-MAG3-BIIB067
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 17, 2026, 7:16 AM EDT